Aldeyra Therapeutics (ALDX) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XBiotech (XBIT) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 24.1% versus a loss of 83.1%. Over five years, XBIT leads with a -86.5% price change compared with -89.1% for ALDX. XBiotech is the larger company by market cap ($52.7 million vs $50.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | XBIT |
|---|---|---|
| Share price | $0.84 | $1.73 |
| Market cap | $50.70M | $52.74M |
| 1-day change | +16.39% | +2.98% |
| YTD return | -83.78% | -27.62% |
| 1-year return | -83.06% | -24.12% |
| 5-year return | -89.06% | -86.48% |
| Forward P/E | — | 13.31 |
| EPS (TTM) | $-0.31 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-33.85M | $-45.54M |
| 52-week high | $5.93 | $2.73 |
| 52-week low | $0.527 | $1.61 |
| Distance from 52-week high | -85.83% | -36.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +685.71% | — |
| Average volume | 1.16M | 64.77K |
| Shares outstanding | 60.36M | 30.49M |
| Employees | 6 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed ALDX by 58.9 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ALDX vs XBIT FAQ
Which is bigger, Aldeyra Therapeutics or XBiotech?
XBiotech (XBIT) is larger, with a market capitalization of $52.74M compared with $50.70M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or XBIT?
XBIT returned -24.12% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.